TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2206058

Group type: EXPERIMENTAL
Intervention: 1% lidocaine dorsal penile nerve block
Number of subjects: 51

Group type: COMPARATOR
Intervention: Saline solution injections
Number of subjects: 51

Group type: COMPARATOR
Intervention: No injections
Number of subjects: 51
Study: 6108392

Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine (2 doses of 40 micrograms)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine (3 doses of 40 micrograms)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Booster dose of Hepatitis B vaccine
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Male patients
Number of subjects: 100
Study: 31216729

Group type: EXPERIMENTAL
Intervention: Random decision forests
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gradient boosting
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Extremely randomized trees
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adaptive boosting
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: K‐nearest neighbors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Shallow neural networks
Number of subjects: 0
Study: 28747328

Group type: EXPERIMENTAL
Intervention: Intermittent low-energy diet (LED) for 5 weeks every 4 months for 3 years
Number of subjects: 153

Group type: COMPARATOR
Intervention: Daily meal replacements of 1-2 meals for 3 years
Number of subjects: 153
Study: 24877791

Group type: EXPERIMENTAL
Intervention: Talking about stories of difficulty (treatment)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Daily events (control)
Number of subjects: 49
Study: 23906400

Group type: EXPERIMENTAL
Intervention: Low-dose L-amlodipine besylate (2.5 mg/d)
Number of subjects: 1051

Group type: EXPERIMENTAL
Intervention: High-dose L-amlodipine besylate (5.0 mg/d)
Number of subjects: 1051

Group type: EXPERIMENTAL
Intervention: Amlodipine maleate (5.0 mg/d)
Number of subjects: 1051
Study: 21434781

Group type: EXPERIMENTAL
Intervention: TM tibial components fixed press-fit by 2 hexagonal pegs
Number of subjects: 50

Group type: COMPARATOR
Intervention: Ti tibial components fixed press-fit and by 4 supplemental screws
Number of subjects: 50
Study: 19595142

Group type: EXPERIMENTAL
Intervention: T0901317, 9‐cis retinoic acid, chenodeoxycholic acid (CDCA) - agonists of LXR, RXR, FXR
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Gallbladder mucosa from GS patients
Number of subjects: 41

Group type: COMPARATOR
Intervention: Gallbladder mucosa from GSF patients
Number of subjects: 41
Study: 16563905

Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg twice daily
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 12740281

Group type: EXPERIMENTAL
Intervention: Routine chest radiographs (CXRs)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Nonroutine chest radiographs (CXRs)
Number of subjects: 94
Study: 11267622

Group type: EXPERIMENTAL
Intervention: Nicotine (21 mg/24 h)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Nicotine (42 mg/24 h)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Mecamylamine (10 mg)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 9675383

Group type: EXPERIMENTAL
Intervention: Epidural/propofol anesthesia (Group P)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Epidural/midazolam anesthesia (Group M)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Epidural/sevoflurane anesthesia (Group S)
Number of subjects: 23
Study: 7860158

Group type: EXPERIMENTAL
Intervention: AIK-C (medium- and standard-titre)
Number of subjects: 2452

Group type: EXPERIMENTAL
Intervention: Edmonston-Zagreb (EZ)
Number of subjects: 2452

Group type: EXPERIMENTAL
Intervention: Leningrad-16
Number of subjects: 2452

Group type: EXPERIMENTAL
Intervention: Schwarz
Number of subjects: 2452

Group type: EXPERIMENTAL
Intervention: All strains of measles vaccine
Number of subjects: 2452

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 2452
Study: 2680162

Group type: EXPERIMENTAL
Intervention: 500 mg/day methylprednisolone for 3 days
Number of subjects: 128

Group type: COMPARATOR
Intervention: 1,000 mg/day methylprednisolone for 3 days
Number of subjects: 128
Study: 788430

Group type: EXPERIMENTAL
Intervention: Dexamethasone 0.5 mg
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Dexamethasone 1.0 mg
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control insulin tolerance test
Number of subjects: 25
Study: 6167516

Group type: EXPERIMENTAL
Intervention: HES 450/0.7
Number of subjects: 20

Group type: COMPARATOR
Intervention: 5% human albumin
Number of subjects: 20
Study: 30678028

Group type: EXPERIMENTAL
Intervention: 24-hour water-only fasting
Number of subjects: 0

Group type: COMPARATOR
Intervention: 24-hour ad libitum fed day
Number of subjects: 0
Study: 28843486

Group type: EXPERIMENTAL
Intervention: Web-based multimedia curriculum (6 self-paced, interactive modules)
Number of subjects: 442

Group type: EXPERIMENTAL
Intervention: Web-based multimedia curriculum (modules)
Number of subjects: 442

Group type: COMPARATOR
Intervention: Readings (control curriculum)
Number of subjects: 442

Group type: EXPERIMENTAL
Intervention: Web-based multimedia curriculum (verbal handoff virtual simulation)
Number of subjects: 442

Group type: EXPERIMENTAL
Intervention: Device-related emergency virtual simulation
Number of subjects: 442
Study: 26766905

Group type: EXPERIMENTAL
Intervention: Dumbbell-training group (DTG)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 45
Study: 24742740

Group type: EXPERIMENTAL
Intervention: Stent loaded with (125)iodine radioactive seeds (irradiation group)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Conventional oesophageal stent (control group)
Number of subjects: 160
Study: 23234491

Group type: EXPERIMENTAL
Intervention: Ditto™ intervention group (receiving Ditto™, procedural preparation and Ditto™ distraction)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group (standard distraction)
Number of subjects: 58
Study: 19912196

Group type: EXPERIMENTAL
Intervention: PVP (potassium-titanyl-phosphate Greenlight 80-W laser ablation system)
Number of subjects: 120

Group type: COMPARATOR
Intervention: TURP (transurethral resection of the prostate)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: PVP
Number of subjects: 120

Group type: COMPARATOR
Intervention: TURP
Number of subjects: 120
Study: 17622003

Group type: EXPERIMENTAL
Intervention: Resorbable collagen barriers supported by osteosynthesis plates
Number of subjects: 22

Group type: COMPARATOR
Intervention: Nonresorbable titanium-reinforced e-PTFE barrier
Number of subjects: 22
Study: 15862370

Group type: EXPERIMENTAL
Intervention: Becker plus figure-of-eight supplementary core suture
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Becker plus anchor supplementary core suture
Number of subjects: 45

Group type: COMPARATOR
Intervention: Becker only
Number of subjects: 45
Study: 12232886

Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training
Number of subjects: 134

Group type: COMPARATOR
Intervention: Bladder training
Number of subjects: 134
Study: 10211919

Group type: EXPERIMENTAL
Intervention: Sertraline (50 mg/day, flexible titration up to 200 mg/day)
Number of subjects: 167

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 167
Study: 7892513

Group type: EXPERIMENTAL
Intervention: Dietary factors (vitamin C and alcohol consumption)
Number of subjects: 175
Study: 2223140

Group type: EXPERIMENTAL
Intervention: Simple mastectomy with postoperative x-ray treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Extended radical mastectomy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Histological grading (grade 1 tumours)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Histological grading (grades 2 and 3 tumours)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Node positive patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Node negative patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Premenopausal women
Number of subjects: 0
Study: 655230

Group type: EXPERIMENTAL
Intervention: Acetazolamide Sequels
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Methazolamide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ethoxzolamide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Acetazolamide tablets
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dichlorphenamide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ascorbic acid placebo
Number of subjects: 0
Study: 31179339

Group type: EXPERIMENTAL
Intervention: Baoshenfang Formula (BSF)
Number of subjects: 0
Study: 28110207

Group type: EXPERIMENTAL
Intervention: Physical Activity Program (10 min warm-up, 20 min rhythmic exercises, 10 min cool-down, 30 min free walking, 4 days a week for 10 weeks)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Physical Activity Program
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 80
Study: 26442396

Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine
Number of subjects: 32

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 32
Study: 23801461

Group type: EXPERIMENTAL
Intervention: Intranasal sodium hyaluronate
Number of subjects: 78

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 78
Study: 21209236

Group type: EXPERIMENTAL
Intervention: Tadalafil 10 mg (TAD) alone
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Tadalafil 10 mg (TAD) with tipranavir/ritonavir (TPV/r) 500/200 mg
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Tadalafil 10 mg (TAD) with steady-state TPV/r
Number of subjects: 17
Study: 20048350

Group type: EXPERIMENTAL
Intervention: Psychoeducational programme (8 sessions over 4 weeks)
Number of subjects: 116
Study: 17291169

Group type: EXPERIMENTAL
Intervention: Computer-tailored intervention
Number of subjects: 337

Group type: COMPARATOR
Intervention: Generic intervention
Number of subjects: 337

Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 337
Study: 15098526

Group type: EXPERIMENTAL
Intervention: 4 mg of ondansetron
Number of subjects: 0

Group type: COMPARATOR
Intervention: 12.5 mg of dolasetron
Number of subjects: 0
Study: 11136177

Group type: EXPERIMENTAL
Intervention: HBV carriers (n = 72)
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: HBV negative (n = 68)
Number of subjects: 195

Group type: COMPARATOR
Intervention: Controls (n = 123)
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Subjects (HBV carriers and HBV negative)
Number of subjects: 195
Study: 9519171

Group type: EXPERIMENTAL
Intervention: MXL capsules (once-daily morphine preparation)
Number of subjects: 85

Group type: COMPARATOR
Intervention: MST Continus tablets (twice-daily morphine preparation)
Number of subjects: 85
Study: 8317754

Group type: EXPERIMENTAL
Intervention: Forced-air warming (approximately 40 degrees C)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Circulating-water mattresses at 40 degrees C
Number of subjects: 99
Study: 2872826

Group type: EXPERIMENTAL
Intervention: Clonidine hydrochloride
Number of subjects: 3

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3
Study: 30858019

Group type: EXPERIMENTAL
Intervention: Randomization methods (8 different methods used)
Number of subjects: 3813

Group type: EXPERIMENTAL
Intervention: Non-normality of baseline variables
Number of subjects: 3813

Group type: EXPERIMENTAL
Intervention: Strength of correlation of baseline variables
Number of subjects: 3813

Group type: EXPERIMENTAL
Intervention: Rounded summary statistics
Number of subjects: 3813
Study: 27862179

Group type: EXPERIMENTAL
Intervention: (S)-ketamine 10 mg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: phenytoin 300 mg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: pregabalin 300 mg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: fentanyl 3 μg kg-1
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: ibuprofen 600 mg
Number of subjects: 16

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 16
Study: 25216597

Group type: EXPERIMENTAL
Intervention: Estrogen plus progestin therapy (EPT+) in normotensive women
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Perindopril (4 mg/day) in hypertensive women
Number of subjects: 100

Group type: COMPARATOR
Intervention: Hydrochlorothiazide (25 mg/day) in hypertensive women
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Estrogen plus progestin therapy (EPT+) with Hydrochlorothiazide in hypertensive women
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Estrogen plus progestin therapy (EPT+) with Perindopril in hypertensive women
Number of subjects: 100
Study: 24334578

Group type: EXPERIMENTAL
Intervention: Nicotine patches over semipermeable membrane dressings (SMD)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Nicotine patches without semipermeable membrane dressings (SMD)
Number of subjects: 28
Study: 22180403

Group type: EXPERIMENTAL
Intervention: HE4 as a serum marker
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CA125 and HE4 screening
Number of subjects: 0
Study: 18083994

Group type: EXPERIMENTAL
Intervention: Preformed tubes
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Reinforced tubes
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Thermosoftened preformed tubes
Number of subjects: 92

Group type: COMPARATOR
Intervention: Upper pathway tubes
Number of subjects: 92
Study: 16249215

Group type: EXPERIMENTAL
Intervention: Paclitaxel 225 mg/m2 every 3 weeks x 4 cycles with concurrent carboplatin AUC 6 every 3 weeks x 4 cycles
Number of subjects: 161

Group type: COMPARATOR
Intervention: Paclitaxel 75 mg/m2/week x 12 with concurrent carboplatin AUC 6 every 3 weeks x 4 cycles
Number of subjects: 161
Study: 12548250

Group type: EXPERIMENTAL
Intervention: Minocycline/rifampin impregnated catheters
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chlorhexidine/silver sulfadiazine impregnated catheters
Number of subjects: 0
Study: 11101062

Group type: EXPERIMENTAL
Intervention: scIL-2 therapy plus antiretroviral therapy
Number of subjects: 72

Group type: COMPARATOR
Intervention: antiretroviral therapy alone (control group)
Number of subjects: 72
Study: 8793221

Group type: EXPERIMENTAL
Intervention: Prosections
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dissection
Number of subjects: 0
Study: 1474180

Group type: EXPERIMENTAL
Intervention: Carbamazepine (CBZ) monotherapy
Number of subjects: 39
Study: 6361793

Group type: EXPERIMENTAL
Intervention: Suprofen 200 mg
Number of subjects: 75

Group type: COMPARATOR
Intervention: Aspirin 650 mg
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 31324597

Group type: EXPERIMENTAL
Intervention: iBASIS-VIPP
Number of subjects: 103

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 103
Study: 30345905

Group type: EXPERIMENTAL
Intervention: Palbociclib plus fulvestrant
Number of subjects: 521

Group type: COMPARATOR
Intervention: Placebo plus fulvestrant
Number of subjects: 521

Group type: EXPERIMENTAL
Intervention: Palbociclib plus fulvestrant (among patients with sensitivity to previous endocrine therapy)
Number of subjects: 521

Group type: COMPARATOR
Intervention: Placebo plus fulvestrant (among patients with sensitivity to previous endocrine therapy)
Number of subjects: 521
Study: 26095256

Group type: EXPERIMENTAL
Intervention: Short-course radiotherapy with surgery delayed 4-8 weeks (SRT-delay)
Number of subjects: 462

Group type: COMPARATOR
Intervention: Short-course radiotherapy with immediate surgery (SRT)
Number of subjects: 462
Study: 23893421

Group type: EXPERIMENTAL
Intervention: Inclusion of a 'psychooncological statement' (PO‐statement) in the discharge summary
Number of subjects: 1416

Group type: EXPERIMENTAL
Intervention: Discharge summary with PO‐statement
Number of subjects: 1416

Group type: COMPARATOR
Intervention: Control group (discharge summary without PO‐statement)
Number of subjects: 1416
Study: 21745388

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment (2 times per week for 12 sessions over 6 weeks)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Waitlist control (no acupuncture treatment for the first 6 weeks)
Number of subjects: 80
Study: 19189783

Group type: EXPERIMENTAL
Intervention: CPAP
Number of subjects: 205

Group type: COMPARATOR
Intervention: Control
Number of subjects: 205
Study: 17114544

Group type: EXPERIMENTAL
Intervention: Real-time single-shot fast spin-echo (RT SSFSE) imaging
Number of subjects: 69

Group type: COMPARATOR
Intervention: Standard single-shot fast spin-echo (SSFSE) imaging
Number of subjects: 69
Study: 15623608

Group type: EXPERIMENTAL
Intervention: Repifermin 25 microg/kg
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Repifermin 50 microg/kg
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 11740974

Group type: EXPERIMENTAL
Intervention: Interferon-alpha (IFNalpha) 3-6 MUI s.c. three/six times a week for 6 months
Number of subjects: 14
Study: 8233298

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy with carboplatin (400 mg/m2 day 1) and 5-fluorouracil (1 g/m2 days 1-5) followed by locoregional treatment (LRT)
Number of subjects: 324

Group type: COMPARATOR
Intervention: Locoregional treatment (LRT) alone
Number of subjects: 324
Study: 2891370

Group type: EXPERIMENTAL
Intervention: 40 mg famotidine orally alone
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: 40 mg famotidine orally with antacid
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: 40 mg famotidine orally with a standard breakfast
Number of subjects: 17
Study: 31972380

Group type: EXPERIMENTAL
Intervention: Remote ischaemic conditioning (RIC)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 58
Study: 28631456

Group type: EXPERIMENTAL
Intervention: Adenosine group (20 mL of bupivacaine hydrochloride 0.375% + 12 mg adenosine in 2 mL of saline 0.9%)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Magnesium group (20 mL of bupivacaine hydrochloride 0.375% + 500 mg magnesium sulphate in 2 mL saline 0.9%)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (20 mL of bupivacaine hydrochloride 0.375% + 2 mL saline 0.9%)
Number of subjects: 0
Study: 27236075

Group type: EXPERIMENTAL
Intervention: 5 weeks positive body exposure (n = 15)
Number of subjects: 28

Group type: COMPARATOR
Intervention: No-treatment condition (n = 13)
Number of subjects: 28
Study: 25688357

Group type: EXPERIMENTAL
Intervention: AJG522
Number of subjects: 0

Group type: COMPARATOR
Intervention: PEG+E
Number of subjects: 0
Study: 23719554

Group type: EXPERIMENTAL
Intervention: 400 μg FA/d
Number of subjects: 119

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 119
Study: 20620713

Group type: EXPERIMENTAL
Intervention: Wave Reflection Index (WRI)
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: Carotid Augmentation Index (cAI(x))
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: Peak backward to peak forward pressure ratio (P(b)/P(f))
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: Increased left ventricular mass index and elevated B-type natriuretic peptide
Number of subjects: 259
Study: 19138244

Group type: EXPERIMENTAL
Intervention: Florajen (probiotic)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 16614274

Group type: EXPERIMENTAL
Intervention: Nicorandil added to existing antianginal treatment
Number of subjects: 0
Study: 12538428

Group type: EXPERIMENTAL
Intervention: Early revascularization (ERV)
Number of subjects: 169

Group type: COMPARATOR
Intervention: Initial medical stabilization (IMS)
Number of subjects: 169
Study: 10649211

Group type: COMPARATOR
Intervention: Investigational drug (placebo-controlled)
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Two-ventricle repair
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Single ventricle palliation
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Preoperative risk model
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Operative risk model (duration of deep hypothermic circulatory arrest)
Number of subjects: 350
Study: 9175213

Group type: EXPERIMENTAL
Intervention: Colonic pouch anastomosis
Number of subjects: 45

Group type: COMPARATOR
Intervention: Straight anastomosis
Number of subjects: 45
Study: 8402740

Group type: EXPERIMENTAL
Intervention: diltiazem 60 mg tid
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: diltiazem SR 120 mg bid
Number of subjects: 10
Study: 3079940

Group type: EXPERIMENTAL
Intervention: PY 108-068 (75 mg/day)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: PY 108-068 (150 mg/day)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 29111391

Group type: EXPERIMENTAL
Intervention: Antimicrobial photodynamic therapy (aPDT) with scaling and root planing (SRP)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Scaling and root planing (SRP) only
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Antimicrobial photodynamic therapy (aPDT) with SRP
Number of subjects: 53
Study: 26593105

Group type: EXPERIMENTAL
Intervention: Expectation of care
Number of subjects: 442

Group type: EXPERIMENTAL
Intervention: Social support
Number of subjects: 442
Study: 25035208

Group type: EXPERIMENTAL
Intervention: FDG-PET
Number of subjects: 135
Study: 21924220

Group type: EXPERIMENTAL
Intervention: Expert feedback after applying an emotionally activating stimulus
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Peer feedback after applying an emotionally activating stimulus
Number of subjects: 218

Group type: COMPARATOR
Intervention: Standard without feedback
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Expert feedback
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Peer feedback
Number of subjects: 218
Study: 20117307

Group type: EXPERIMENTAL
Intervention: NeuFlex implants
Number of subjects: 33

Group type: COMPARATOR
Intervention: Swanson implants
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 33
Study: 18180637

Group type: EXPERIMENTAL
Intervention: Topical 5% lidocaine
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Topical 5% amitriptyline
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 15917384

Group type: EXPERIMENTAL
Intervention: Sargramostim (6 mug/kg/day for 56 days)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124
Study: 12526955

Group type: EXPERIMENTAL
Intervention: L-NMMA (12.5, 25, and 50 microg/kg/min for Low; 25, 50, and 100 microg/kg/min for High)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (saline infusions only)
Number of subjects: 10
Study: 10563070

Group type: EXPERIMENTAL
Intervention: Valsartan 80 mg once daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Captopril 25 mg twice daily
Number of subjects: 0